- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05616377
Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation (CLTBME)
November 8, 2022 updated by: Yonggao Mou, Sun Yat-sen University
Survival Benefit of Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation: A Multicenter Retrospective Study
The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are:
- Is local therapy performed before or after target therapy would provide survival benefit ?
- What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lun Liang, PHD
- Phone Number: 18277186779
- Email: lianglun@sysucc.org.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First Affiliated Hospital of Guangxi Medical University will be selected.
Description
Inclusion Criteria:
- Evidence of pathological diagnosis of primary tumor.
- Brain metastases confirmed by enhanced magnetic resonance imaging.
- Gene test indicated that EGFR mutation.
- Complete clinical information.
Exclusion Criteria:
- If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery.
- Patients with 2 or more types of tumors.
- Incomplete clinical information.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
target therapy + local therapy group vs target therapy alone group
|
Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group.
Participants who underwent target therapy alone were divided into target therapy alone group
|
local therapy before target therapy group vs local therapy after target therapy group
|
Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group.
Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
|
Overall survival
|
From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: From date of first follow-up until the date of first documented progression, assessed up to 120 months
|
Progression-free survival
|
From date of first follow-up until the date of first documented progression, assessed up to 120 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 20, 2022
Primary Completion (ANTICIPATED)
August 20, 2023
Study Completion (ANTICIPATED)
November 20, 2024
Study Registration Dates
First Submitted
November 8, 2022
First Submitted That Met QC Criteria
November 8, 2022
First Posted (ACTUAL)
November 15, 2022
Study Record Updates
Last Update Posted (ACTUAL)
November 15, 2022
Last Update Submitted That Met QC Criteria
November 8, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EGFR+BM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
Istituto Clinico HumanitasRecruitingBrain Metastases, AdultItaly
-
Mustafa Khasraw, MBChB, MD, FRCP, FRACPDaiichi SankyoNot yet recruitingA Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer)Brain Metastases, AdultUnited States
-
Istituto Clinico HumanitasBrainlabRecruitingBrain Metastases, AdultItaly
-
Universitaire Ziekenhuizen KU LeuvenRecruitingBrain Metastases, AdultBelgium
-
University Hospital, GrenobleNH TherAguix SASRecruitingRadiotherapy | Brain Metastases, AdultFrance
-
Centre de recherche du Centre hospitalier universitaire...Université de SherbrookeActive, not recruitingBrain Metastases, AdultCanada
-
Juergen DebusHeidelberg UniversityCompletedBrain Metastases, AdultGermany
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
Clinical Trials on Surgery or Radiotherapy
-
Maastricht Radiation OncologyCompletedNon-small Cell Lung Cancer | Stage IV (Oligo-metastases)Netherlands
-
Universitaire Ziekenhuizen KU LeuvenActive, not recruitingCastration-resistant Prostate CancerBelgium
-
Swiss Group for Clinical Cancer ResearchRecruitingNon-small Cell Lung Cancer (NSCLC) | Stage IVSwitzerland
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Eye & ENT Hospital of Fudan UniversityCancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingMucosal Melanoma | Sinonasal MelanomaChina
-
Fengming KongThe University of Hong KongRecruiting
-
Shanghai Pulmonary Hospital, Shanghai, ChinaJiangsu HengRui Medicine Co., Ltd.Not yet recruitingLimited Stage Small Cell Lung CancerChina
-
Korea Cancer Center HospitalGachon University Gil Medical Center; The Catholic University of Korea; Gangnam... and other collaboratorsUnknownRectal Cancer | Liver Metastasis | Lung MetastasisKorea, Republic of
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNanfang Hospital of Southern Medical UniversityNot yet recruiting
-
National Cancer Center Hospital EastJapan Agency for Medical Research and Development; Japan Clinical Oncology...Recruiting